Peter McCullough on health: what the evidence says · JRE #1747

What the evidence says 01 / RECORD

McCullough's 13% permanent-injury estimate is derived from a pre-COVID study of classic (non-vaccine) myocarditis natural history, not from data on COVID-19 vaccine-associated myocarditis itself, and he explicitly frames it as an inference ("I'm applying data from other forms of myocarditis before COVID") rather than a measured outcome from vaccine-associated cases. The largest available follow-up data on pediatric and young-adult vaccine-associated myocarditis point the other way: a 38-hospital U.S. study of 333 cases (Jain et al., 2024, eClinicalMedicine/MACiV) found the initial clinical course was mild in 80% of patients, cardiac dysfunction was present in only 17% at presentation (versus 68% in MIS-C), and no cardiac deaths or transplants had occurred through a median follow-up of about six months, though residual scarring (late gadolinium enhancement) persisted in 60% of patients despite normal or near-normal pump function. A separate one-year follow-up cohort (Truong et al., 2023, Circulation) similarly tracked recovery of cardiac function over time in this population. Current pediatric cardiology literature characterizes vaccine-associated myocarditis as generally mild with favorable short- to mid-term functional recovery, while flagging persistent imaging findings as warranting longer-term study; no published cohort of vaccine-associated myocarditis has reported a 13% rate of permanent heart failure or lasting functional impairment. The claim is best characterized as a speculative extrapolation from an unrelated disease population rather than an evidence-based projection.